Changing trends in tissue acquisition in malignant pancreatic neoplasms

Roy, Ann; Kim, Micheline; Hawes, Robert H.; Varadarajulu, Shyam

doi:10.1111/jgh.13081

Cited by 16 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although EUS‐FNA is the current modality of choice for tissue acquisition in patients with pancreatic mass lesions, reliable procurement of histological tissue remains a challenge. Given the technical limitations associated with the use of Tru‐cut biopsy needles and the lack of difference between the ProCore and standard FNA needles a novel fork‐tip biopsy needle (SharkCore; Medtronic Inc., Boston, MA, USA) was recently developed to procure histology samples.…”

Section: Discussionmentioning

confidence: 99%

Endoscopic ultrasonography‐guided biopsy using a Franseen needle design: Initial assessment

Bang

Hébert‐Magee

Hasan

et al. 2016

Digestive Endoscopy

Self Cite

120

119

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Endoscopic ultrasonography‐guided biopsy using a Franseen needle design: Initial assessment

Bang

Hébert‐Magee

Hasan

et al. 2016

Digestive Endoscopy

Self Cite

120

119

View full text Add to dashboard Cite

show abstract

“…A 5-year retrospective claims analysis of Medicare patients undergoing sampling of pancreatic malignancies showed an ongoing trend towards EUS-guided sampling. However, in spite of higher costs, the application of percutaneous image-guided sampling remained prevalent in particular outside major academic and urban hospitals [195].…”

Section: Eus-guided Sampling: Indications and Clinical Impact !mentioning

confidence: 99%

EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part IV – EUS-guided Interventions: General aspects and EUS-guided sampling (Long Version)

et al. 2015

View full text Add to dashboard Cite

The fourth part of the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) Guidelines on Interventional Ultrasound describes general aspects of endoscopic ultrasound-guided diagnostic and therapeutic interventions and assesses the evidence for endoscopic ultrasound-guided sampling. Endoscopic ultrasound combines the most advanced high-resolution ultrasound imaging of lesions within the wall and in the vicinity of the gastrointestinal tract and safe and effective fine needle based tissue acquisition from these lesions. The guideline addresses the indications, contraindications, techniques, adverse events, training and clinical impact of EUS-guided sampling. Advantages and drawbacks are weighed in comparison with image-guided percutaneous biopsy. Based on the most current evidence, clinical practice recommendations are given for crucial preconditions and steps of EUS-guided sampling as well as for safe performance. Additionally, the guideline deals with the principles and reliability of cytopathological reporting in endoscopic ultrasound-guided sampling (long version).

show abstract

“…The use of FNA biopsy in the management of pancreatic tumors has been well established. Whereas pancreatic FNA routinely applies CS for diagnosis, previous studies have shown that the diagnostic performance of pancreatic FNA partly depends on the rapid assessment provided by cytologists [2][3][4][5][6]. ROSE ensures the effectiveness of biopsy and avoids inadequate sampling.…”

Section: Introductionmentioning

confidence: 99%

“…Such issues could be easily overcome by the use of ROSE. ROSE helps to evaluate on-site sampling, decrease inadequate samples and improve the diagnostic rate by 10-30%[2][3][4][5][6]. However, due to labor and time requirements, ROSE is hardly used.…”

mentioning

confidence: 99%

Thinprep® test versus conventional smear for the detection of pancreatic neoplasms after percutaneous ultrasound-guided fine-needle aspiration biopsy

Tan

Zhou

Gui

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Few studies have defined the diagnostic value of ThinPrep pap test (a liquid-based cytology) for pancreatic samples obtained by percutaneous fine-needle aspiration (FNA). This study aimed to compare the efficacy of ThinPrep cytologic test (TCT) in screening pancreatic neoplasms to the conventional smear (CS), especially in the absence of rapid on-site evaluation (ROSE). Methods The study evaluated 78 patients with suspected pancreatic tumors who underwent percutaneous ultrasound-guided fine-needle aspiration (US-FNA) combined with CS and TCT. Final disease diagnosis was based on biopsy, surgery, or clinical progress. Results The sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) of TCT were 95.8%, 100%, 96.1%, 100%, 62.5%, whereas the values for CS were 90.1%, 100%, 90.8%, 100%, 41.7%, respectively. The combination of CS and TCT recorded 98.6%, 100%, 98.7%, 100%, 83.3%, respectively, for the parameters evaluated. None of the participants recorded serious complications. Conclusions This study shows that TCT is a more reliable tool in the detection of pancreatic neoplasms, especially for percutaneous US-FNA samples. Whereas TCT may be used as an alternative to CS in the absence of ROSE, the use of both methods in the screening process yields better results.

show abstract

Changing trends in tissue acquisition in malignant pancreatic neoplasms

Cited by 16 publications

References 21 publications

Endoscopic ultrasonography‐guided biopsy using a Franseen needle design: Initial assessment

Endoscopic ultrasonography‐guided biopsy using a Franseen needle design: Initial assessment

EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part IV – EUS-guided Interventions: General aspects and EUS-guided sampling (Long Version)

Thinprep® test versus conventional smear for the detection of pancreatic neoplasms after percutaneous ultrasound-guided fine-needle aspiration biopsy

Contact Info

Product

Resources

About